Table 4 Clinical and demographic characteristics of patients who died and those who survived
Died (n = 28) | Survived (n = 63) | P-value | |
|---|---|---|---|
Male sex | 24 (85.7) | 42 (66.7) | 0.06 |
Age, years* | 66.85 (41–84) | 65.5 (24–87) | 0.12 |
APACHE II* | 14 (5–27) | 10.5 (2–28) | 0.047 |
Co-morbidities, n (%): | |||
Malignancy | 6 (21.4) | 8 (12.7) | 0.35 |
Cardiovascular | 7 (25) | 19 (30.2) | 0.8 |
Pulmonary | 15 (53.6) | 18 (28.6) | 0.03 |
Diabetes Mellitus | 3 (10.7) | 18 (28.6) | 0.1 |
Urogenitala | 6 (21.4) | 8 (12.7) | 0.35 |
Hepatic | 4 (14.3) | 4 (6.3) | 0.24 |
Haematologicalb | 4 (14.3) | 8 (12.7) | 1 |
Neurologicalc | 2 (7.1) | 16 (23.4) | 0.05 |
Charlson* | 5 (1–9) | 4 (0–10) | 0.039 |
McCabe** | 1.8 ± 0.7 | 1.3 ± 0.6 | 0.008 |
Clinical status, n (%) | |||
Severe sepsis | 15 (53.6) | 43 (68.3) | 0.17 |
Shock | 2 (7.1) | 5 (7.9) | 0.89 |
Patients with CKD at baseline | 7 (25) | 12 (19) | 0.52 |
Department of hospitalization: | |||
Medical | 12 (42.9) | 32 (50.8) | |
Surgical | 11 (39.3) | 21 (33.3) | 0.78 |
ICU2 | 5 (17.9) | 10 (15.9) | |
Admission diagnosis category: | |||
Infection | 7 (25) | 19 (30.2) | |
Other-medical | 12 (42.9) | 23 (36.5) | 0.82 |
Other-surgical | 9 (32.1) | 21 (33.3) | |
CMS daily dose (millions IU)** | 5.5 ± 2.4 | 5.4 ± 2.2 | 0.793 |
CMS total dose (millions IU)** | 114.4 ± 116.5 | 113.3 ± 91.5 | 0.68 |
CMS duration of treatment, days** | 20.3 ± 16.5 | 21.4 ± 16.6 | 0.88 |
Combined treatment, n (%) | 15 (53.6) | 31 (49.2) | 0.7 |
Css (mg/L)** | 2,1 ± 1.4 | 1.4 ± 1,4 | 0.011 |
Css > 1.25 (mg/L), n (%) | 18 (64.3) | 28 (44.4) | 0.093 |
Css/MIC** | 4.2 ± 2.7 | 3.1 ± 3 | 0.048 |
AKI at day 7, n (%) | 14 (50) | 16 (25.4) | 0.021 |
AKI at the EOT, n (%) | 20 (71.4) | 29 (46) | 0.025 |
Length of hospital stay, (days)** | 65.2 ± 33.9 | 71.5 ± 63.2 | 0.3 |